CNN reports that Englands PPL Therapeutics, the biotech firm that brought us Dolly, has just been put on the block. The report notes:
The move is a fresh blow to Europes struggling biotech industry, which has achieved only a fraction of the success of its U.S. counterpart, and highlights the difficulty companies face in making money from scientific breakthroughs.
Just another example of why the United States need not yet fear the much dreaded "biotech brain-drain" that human cloning proponents predict every time a call is made for anti-cloning regulations.
Discussions - No Comments Yet
Leave a Comment